1.
$Moderna, Inc.(MRNA)$ CEO remains confident about respiratory vaccines franchise going forward:
• Stabilization of covid vaccine market in elderly and high risk patients and growth potential in international starting in 2026 (10y contracts)
• Demand could be strong for covid/flu combo (2026/2027 possible approval based on this summer flu efficacy data).
• Cost is going to decrease and revenue is expected to grow in next years.
• mRNA platform is far more efficient in terms of operating expenses and scalability of manufacturing.
Image
For whom haven't open CBA can know more from below:
🏦 Open a CBA today and enjoy privileges of up to SGD 20,000 in trading limit with 0 commission. Trade SG, HK, US stocks as well as ETFs unlimitedly!
Find out more here：
Talk with Tiger PM
Share your product feedback, ideas, and experiences with TigerPM here, and we will respond as soon as possible.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments